NAGE Niagen Bioscience Inc

$NAGE my wife who's breastfeeding swears that niagen increases breast milk production. Initially she was hesitant to take it until she saw the start of the clinical trial. They are going to hit something big

$NAGE Bad news for our old enemies Elysium. "US Court of Appeals reversed a $9.15 million attorneys' fee award that the District of Delaware had ordered ChromaDex to pay Elysium. ChromaDex no longer owes those fees, and the court refused to even send the case back for a second look."

$NAGE in the canaccord genuity interview at the end Rob Fried mentions they have a deal with Este Lauder to bring out a skin cream in the first quarter and are in talks with another company.as well

$NAGE Ahead of earnings... Canaccord Genuity has officially maintained its Buy rating on Niagen Bioscience while lowering its price target from $10 to $9. The update was issued by analyst Susan Anderson. Even with the minor reduction to a $9 price target, the new estimate still represents massive forecasted upside (roughly 286%) from the stock's recent closing price of $2.33.

$NAGE Niagen Bio remains in Russell. 2000. AI: "How does Niagen Bioscience's performance compare to other companies in the Russell 2000? Niagen Bioscience (NASDAQ: NAGE) has a market capitalization of approximately $184.36 million and a P/E ratio of 11.65, which is lower than the average P/E ratio of 33.1 for the Russell 2000. This indicates that Niagen may be undervalued compared to its peers in the index."

$NAGE winning the court case against Elysium also frees up any cash flow going forward that they might have previously segregated against the possibility of that they would have loss the appeal

$NAGE I am assuming they are holding off by shares at this time to spend their cash on nanocloud product launch ,and other corporate initiatives coming up in the early part of 2027

$NAGE Observation from call. Rob Fried (CEO) said he didn't think they were on Amazon yet for the Nanocloud product, but it has actually been up since about 10/20 and has 50+ sales with 3 reviews at 5 stars as of today. It is listed at $59 for 30 sachets. I will be curious to see how the sales volume increases over the next 12 months.

$NAGE AI Overview AI - what is Analysts value Niagen Bioscience, Inc. (NASDAQ: NAGE) with an average 12-month price target of $12.08 (ranging from a low of $8.50 to a high of $22.00), and carry an overall consensus rating of Strong Buy. Analyst Price Targets & Forecasts Average Price Target: $12.08 per share, representing roughly 383% upside from recent trading levels around $2.53 – $2.58. Low Estimate: $8.50 per share High Estimate: $22.00 per share Consensus Rating: Major brokerages list the stock as a Strong Buy based on covering analysts from firms like Canaccord Genuity and H.C. Wainwright. Fair Value Estimates: Independent equity research platforms like .... estimate intrinsic fair value around $9.00 to $12.60 per share.

$NAGE released its first Tru Niagen skincare product, NanoCloud, a dermatologist-tested, waterless sachet for anti-aging skin care.

$NAGE While there is understandable negative sentiment, I want to point out that for a newly classed biotech this company is unique. It has an established retail brand that provides cash flow in a domaine where existing companies can be heavily dependent on gov't funding and milestones while running negative cash flow. As has been noted nb4168 novel/accelerated designations may garner funding that will assist the existing POSITIVE cash balance. glta

$NAGE Q3 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.01 down -120.00% YoY • Reported revenue of $27.19M down -20.01% YoY

$NAGE An interesting call the day of earnings: H.C. Wainwright lowered its price target on Niagen Bioscience stock to $10 from $11 while maintaining a Buy rating.

$NAGE Taken from JAMA. Among patients with early Parkinson disease, nicotinamide riboside treatment for 52 weeks did not improve clinical outcomes and was associated with worse clinical outcomes than placebo. These findings do not support nicotinamide riboside as a disease-modifying treatment for Parkinson disease. This company can not catch a break.

$NAGE Any CC thoughts? Earnings at 0.00 maybe slightly positive at the expense of their current cash balance in order to avoid SP shock of neg earnings. Optimism - adoption and demand in SQ and IV and derm, with additional partnerships. EL commits. Pessimism - COL blunts expansion in some, or all of the above. CFO addresses financing and cash balance. (My recent hobbyhorse is a revolver into T-bills) Wildly curious to get color on 4168 financing: balloon payment(s), continuous drips? When will be biggest $$ hit? I encourage querying IND milestones for what's required of nage for a successful application. Much of this can occur in parallel. Please criticize and/or add. I accept all mockery.